This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Soltamox, Liquid Version Of Tamoxifen Citrate (Photo: Business Wire)

Breast Cancer Awareness Month raises visibility and research dollars to address a disease that in the United States claims nearly 40,000 lives annually and affects approximately 240,000 people who each year are newly diagnosed. While the month’s activities are important in the fight against breast cancer, they are not designed to directly improve the day-to-day management of the disease. But today, a liquid version of one of the most common drugs prescribed to fight breast cancer, tamoxifen, has for the first time become available in the United States under the brand name Soltamox® (tamoxifen citrate). Soltamox may offer patients who need tamoxifen therapy an important treatment option. Introduced by DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology supportive care products, Soltamox, a prescription medication, is expected to be available in pharmacies nationwide starting October 22.
Soltamox, liquid version of tamoxifen citrate (Photo: Business Wire)

Soltamox, liquid version of tamoxifen citrate (Photo: Business Wire)

Why liquid tamoxifen?

According to a 2011 study published in The Lancet, a five-year course of tamoxifen treatment in women with estrogen-receptor-positive breast cancer cut their risk of death by about one-third over a 15-year period. Unfortunately, for some people with breast cancer, the pill form of tamoxifen can be difficult to swallow due to a variety of reasons, including the effects of radiation, surgery and chemotherapy. Some people simply prefer liquid medications over pills or hope to reduce the number of pills they need to take on a daily basis.

Swallowing difficulties

Liquid medications may be appropriate for people who have difficulty or discomfort swallowing solid content. People who have trouble swallowing pills may miss doses of prescribed medications or discontinue them entirely. “Treatment of breast cancer with tamoxifen is a long-term commitment for patients if they are to have the best chance of preventing the disease from recurring,” said oncologist Jivesh Sharma, MD, clinical faculty member at Presbyterian Hospital in Dallas, Texas. “A liquid version of tamoxifen may help people with breast cancer stay on their tamoxifen therapy.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.21 -1.00%
FB $118.16 0.62%
GOOG $699.24 0.99%
TSLA $228.49 -1.60%
YHOO $35.78 -0.65%


Chart of I:DJI
DOW 17,659.14 -91.77 -0.52%
S&P 500 2,050.11 -13.26 -0.64%
NASDAQ 4,727.0990 -36.1250 -0.76%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs